Property-based design: Optimization of drug absorption and pharmacokinetics

Journal of Medicinal Chemistry

Volumn 44, Issue 9, 2001, Pages 1313-1333

  Van de Waterbeemd, H ^a   Smith, D A ^a   Beaumont, K ^a   Walker, D K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETAXOLOL; CYTOCHROME P450; DILTIAZEM; DOFETILIDE; FELODIPINE; GLYCOPROTEIN P; INDINAVIR; METOPROLOL; MIDAZOLAM; NIFEDIPINE; NITRENDIPINE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; SULFANILAMIDE; TALINOLOL; UK 224671; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG SOLUBILITY; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE TRANSPORT; NONHUMAN; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CELL MEMBRANE; DRUG DESIGN; EYE; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NASAL MUCOSA; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRODRUGS; SKIN ABSORPTION;

EID: 0035953319     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000407e     Document Type: Review

References (223)

1. Permeabilitätsstudien an Chara eratophylla
2. Permeability of red cell membranes to small hydrophilic and lipophilic solutes
3. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
4. A scoring scheme for discriminating between drugs and nondrugs
5. Potential drugs and nondrugs: Prediction and identification of important structural features
6. Designing libraries with CNS activity
7. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
8. Evaluation and prediction of drug permeation
9. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity
10. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases
11. Property distribution of drug-related chemical databases
12. Chemoinformatics - Predicting the physicochemical properties of "drug-like" molecules
13. Considerations for the use of computational chemistry techniques by medicinal chemists
14. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
15. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
16. Theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
17. The fundamental variables of the biopharmaceutics classification system (BCS): A commentary
18. Disposition and metabolism of atenolol in animals
19. Pharmacokinetic studies with atenolol in the dog
20. Metabolism of atenolol in man
21. 1-adrenoceptors, in mice, rats, rabbits, dogs and humans
22. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers
23. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides
24. The pharmacological role of P-glycoprotein in the intestinal epithelium
25. Enzyme catalysed processes of first-pass hepatic and intestinal drug extraction
26. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical
27. Metabolism and transport of the macrolide immunosuppresant sirolimus in the small intestine
28. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
29. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues
30. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
31. Interindividual variation in intestinal mdr1 expression: Lack of shorOLINIT-term diet effects
32. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
33. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison
34. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
35. Molecular and physical mechanisms of first pass extraction
36. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
37. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation
38. A general pattern for substrate recognition by P-glycoprotein
39. Structure-activity relationship of P-glycoprotein substrates and modifiers
40. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics
41. Speculations on the substrate structure-activity relationship (SSAR) of cyochrome P450 enzymes
42. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
43. HIV-1 protease inhibitors are substrates for the MDR1 Multidrug transporter
44. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
45. Role of P-glycoprotein in the secretory mechanism of quinidine absorption from rat small intestine
46. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein
47. The contribution of intestinal secretion to the dose dependent absorption of celiprolol
48. In vivo nonlinear intestinal permeability of celiprolol and propanolol in conscious dogs: Evidence for intestinal secretion
49. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration and dose dependent absorption in vitro and in vivo
50. 3H]-verapamil radioligand binding assay
51. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
52. Disposition and bioavailability of the β-adrenoceptor antagonist talinolol in man
53. Direct demonstration of small intestinal secretion and site dependent absorption of the β-blocker talinolol in humans
54. 2 antagonist in rat, dog and human
55. 2 antagonist, UK-224,671
56. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine A
57. First-pass metabolism of midazolam by the human intestine
58. The pharmacokinetics of midazolam in man
59. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
60. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
61. Active secretion and enterocytic drug metabolism barriers to drug absorption
62. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats
63. Pharmacokinetics of felodipine in patients with liver disease
64. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4. Implications for interindividual variability in disposition, efficacy, and drug interactions
65. Comparative assessment of D-xylose absorption between small intestine and large intestine
66. Intestinal absorption of peptides
67. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin
68. Mannitol, as a marker for intestinal integrity in in vitro absorption studies
69. Chemical approaches to improve the oral bioavailability of peptidergic molecules
70. Jejunal permeability: A comparison between the Ussing chamber technique and the single-pass perfusion in humans
71. Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability
72. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates
73. Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption
74. An investigation of the rat in situ absorption model using practolol and propranolol
75. Gastric, intestinal and colonic absorption of a series of β-blockers in the rat
76. Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ and in vivo absorption
77. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans
78. Caco-2 momolayers in experimental and theoretical predictions of drug transport
79. The influence of peptide structure on transport across Caco-2 cells
80. CYP3A-like cytochrome P450-mediated metabolism and polarised efflux of cyclosporin A in Caco-2 cells
81. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption
82. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments
83. 1 and Caco-2 cell lines as models for studying intestinal paracellular absorption
84. MDCK (Madin-Darby Canine Kidney) cells: A tool for membrane permeability screening
85. Analysis of drug transport and metabolism in cell monolater systems that have been modified by cytochrome P4503A4 cDNA-expression
86. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein
87. Structure-activity relationship studies of propafenone analogues based on P-glycoprotein ATPase activity measurements
88. Pharmacokinetics and metabolism in early drug discovery
89. High-throughput measurements of solubility profiles
90. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates
91. a values based on a pH gradient flow-injection system
92. Lipophilicity profiles: Theory and measurement
93. pH-metric log P. II: Refinement of partition coefficients and ionization constants of multiprotic substances
94. pH-metric log P 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs
95. Membranes and their models: Towards a rational choice of partitioning system
96. Intermolecular forces expressed in 1,2-dichloroethane-water partition coefficients
97. Structure-lipophilicity relationships of neutral and protonated β-blockers
98. Immobilized artificial membranes - Screens for drug membrane interactions
99. Immobilized-artificial-membrane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability
100. Use of immobilized artificial membrane chromatography for drug transport applications
101. IAM retention and blood brain barrier penetration
102. Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier
103. Immobilised liposome chromatography of drugs for model analysis of drug-membrane interactions
104. The applicability of computational chemistry in the evaluation and prediction of drug transport properties
105. Determination of liposome partitioning of ionizable drugs by titration
106. Congeneric behavior in estimations of octanol-water partition coefficients by micellar electrokinetic chromatography
107. The parametrization of lipophilicity and other structural properties in drug design
108. 2 receptor histamine antagonists
109. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport and cationic drugs
110. Review of theoretical passive drug absorption models: Historical background, recent developments and limitations
111. Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety
112. Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects
113. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: Importance of drug ionisation in the in vitro prediction of in vivo absorption
114. Prediction of physicochemical parameters by atomic contributions
115. ACD Labs/logP dB 3.5 and ChemSketch 3.5
116. Calculating log P(oct) with no missing fragments; The problem of estimating new interaction parameters
117. The hydrophobic fragmental constant approach for calculating log P in octanol/water and aliphatic hydrocarbon/water systems
118. Octanol-water partition: Searching for predictive models
119. Computational approaches to lipophilicity: Methods and applications
120. Substructure and whole molecule approaches for calculating log P
121. Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs
122. Estimation of Caco-2 cell permeability using calculated molecular descriptors
123. Application of MS-WHIM descriptors: 3. Prediction of molecular properties
124. Comparison of passive drug transport through Caco-2 cells and artificial membranes
125. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes
126. High-throughput artificial membrane permeability studies in early lead discovery and development
127. Physicochemical parameters as tools in drug discovery and lead optimization
128. A new interpretation of salicylic acid transport across the lipid bilayer: Implications of pH-dependent but not carrier-mediated absorption from the gastrointestinal tract
129. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption
130. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach
131. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
132. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors
133. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
134. Polar intermolecular interactions encoded in partition coefficents: An indirect estimation of hydrogen-bond parameters of polyfunctional solutes
135. Applications of a solvation equation to drug transport properties
136. Azole endothelin antagonists. 3. Using Δlog P as a tool to improve absorption
137. Physicochemical and drug-delivery considerations for oral drug bioavailability
138. Quantitative structure-absorption relationships
139. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors
140. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption
141. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics
142. Molecular field-derived descriptors for the multivariate modeling of pharmacokinetic data
143. Toward minimalistic modeling of oral drug absorption. 1
144. Molecular fields on quantitative structure-permeation relationships: The Volsurf approach
145. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship
146. On the partition of ampholytes: Application to blood-brain distribution
147. QSAR model for drug human bioavailability
148. Blood-brain barrier permeation: Molecular parameters governing passive diffusion
149. Molecular factors influencing drug transfer across the blood-brain barrier
150. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration
151. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modelling
152. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics
153. Computation of brain-blood partitioning of organic solutes via free energy calculations
154. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
155. Predicting blood-brain barrier permeation from three-dimensional molecular structure
156. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists
157. The functional role of P-glycoprotein in the blood-brain barrier
158. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
159. In vitro models of the blood-brain barrier to polar permeants: Comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells
160. Estimating skin permeation. The validation of five mathematical skin permeation models
161. Percutaneous absorption: A multiple pathway model
162. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents
163. Investigation of the mechanism of flux across human skin in vitro in quantitative structure-permeability relationships
164. A new method for estimating dermal absorption from chemical exposure: 2. Effect of molecular weight and octanol-water partitioning
165. A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity
166. Epidermal permeability - Penetrant structure relationships: 3. The effect of hydrogen bonding interactions and molecular size on diffusion across the stratum corneum
167. Epidermal permeability-penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge
168. Relationship between H-bonding of penetrants to stratum corneum lipids and diffusion
169. A comparative in vitro study of percutaneous penetration of β-blockers in human skin
170. Unified model for the corneal permeability of related and diverse compounds with respect to their physicochemical properties
171. The influence of lipophilicity upon the nasal absorption of a series of hexapeptides
172. Nasal delivery of peptides: An in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium
173. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)
174. Pharmacodynamics of variable patient compliance: Implications for pharmaceutical value
175. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
176. Amlodipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease
177. Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey
178. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat
179. Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical significance of hepatic and/or renal clearance
180. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
181. The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs
182. Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species
183. The allometric approach for interspecies scaling of pharmacokinetic parameters
184. Fluconazole: Interspecies scaling and allometric relationships of pharmacokinetic properties
185. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
186. In vivo pharmaco-kinetics of felodipine predicted from in vitro studies in rat, dog and man
187. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide
188. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man
189. Use of in vitro metabolism studies in drug development: An industrial perspective
190. Reduced dimension HPLC columns as a practical tool for rapid separations in drug discovery
191. Rapid scanning technique for the determination of optimal tandem mass spectrometric conditions for quantitative analysis
192. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques
193. A physiological approach to hepatic drug clearance
194. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
195. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol
196. Metabolism and structure activity data based drug design: Discovery of (-)SCH 53079 an analog of the potent cholesterol absorption inhibitor (-)SCH 48461
197. Synthesis of a series of compounds related to betaxolol, a new β1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases
198. Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones
199. 5-, 6-, 7- and 8-Amino-2-(N, N-di-n-propylamino)-1,2,3,4-tetrahydronaphthalenes: Centrally acting DA and 5-HT1A agonists
200. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily
201. Felodipine kinetics in healthy men
202. Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration
203. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects
204. Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man
205. Design and application of prodrugs
206. Soft drug design. General principles and recent applications
207. Permeability of 5-fluorouracil and prodrugs in Caco-2 cell monolayers
208. Structure-metabolism relations, and the challenge of predicting biotransformation
209. Three- and four-dimensional quantitative structure-activity relationship analyses of cytochrome P-450 3A4 inhibitors
210. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
211. Molecular modeling approaches to predict metabolism and toxicity
212. Lipophilicity and metabolites and its role in biotransformation
213. The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples
214. Insight into the lipophilicity of the aromatic N-oxide moiety
215. Intrinsic and intramolecular lipophilicity effects in O-glucuronides
216. An assessment of the reaction energetics for cytochrome P450-mediated reactions
217. Predicting human oral bioavailability of a novel quantitative structure-bioavailability relationship